Diabetic retinopathy remains one of the leading causes of blindness in working-aged adults worldwide. The main causes of vision loss from diabetic retinopathy are proliferative diabetic retinopathy and diabetic macular edema. Laser photocoagulation has been the mainstay of treatment for limiting vision loss in both proliferative diabetic retinopathy and diabetic macular edema since the 1980s.1, During the last 2 decades, vascular endothelial growth factor (VEGF) has been shown to have a key role in the pathogenesis of diabetic retinopathy, and intraocular (intravitreal) injections of anti-VEGF agents have become standard care for patients with diabetic macular edema, supplanting focal or grid laser photocoagulation.3

This content was originally published here.